HDAC inhibitors synergize antiproliferative effect of sorafenib in renal cell carcinoma cells. [electronic resource]
Producer: 20121015Description: 3161-8 p. digitalISSN:- 1791-7530
- Antineoplastic Agents -- pharmacology
- Benzenesulfonates -- pharmacology
- Carcinoma, Renal Cell -- genetics
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Enzyme-Linked Immunosorbent Assay
- Flow Cytometry
- Histone Deacetylase Inhibitors -- pharmacology
- Humans
- Hydroxamic Acids -- pharmacology
- Kidney Neoplasms -- genetics
- Niacinamide -- analogs & derivatives
- Phenylurea Compounds
- Pyridines -- pharmacology
- Sorafenib
- Sulfonamides
- Von Hippel-Lindau Tumor Suppressor Protein -- genetics
- Vorinostat
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.